Protocol

NECTAR: A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide) in T-ALL Relapse: A Joint Study of TACL and POETIC

Diseases

Leukemias / Lymphomas : Leukemia

Description

This is a research study for patients who have relapsed T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LL). Relapse means the leukemia or lymphoma has come back after treatment. Nelarabine is a drug approved by the FDA (Food and Drug Administration) for treating children and adults with T-ALL and T-LL. This research study will use nelarabine with two other cancer fighting drugs. Nelarabine (Arranon®) will be used together with etoposide (VePesid®, VP-16) and cyclophosphamide (Cytoxan®).

Nelarabine has been used by itself to treat children and adults with relapsed T-ALL and T-LL. Nelarabine has not been tested in combination with the other chemotherapy drugs used in this study. This is a Phase I study. In a phase I study drugs are tested to the highest dose that can be safely given. Drugs are given at gradually increasing dosages until there are unacceptable side effects. The goal of the Phase I study is to find out the doses of nelarabine, etoposide and cyclophosphamide that can be safely given for 5 days.


Objectives


Eligibility


For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE  (1-866-278-5833).


Contact

Deepa Bhojwani, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN  38105  USA
Phone: 1-866-2ST-JUDE (1-866-278-5833)
FAX: 901-595-5068

Referring or consulting physicians only: protocolinfo@stjude.org

For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

 

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.